Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Sep 25;12(9):e0185105.
doi: 10.1371/journal.pone.0185105. eCollection 2017.

Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis

Baba Maiyaki Musa  1   2 , Aishatu L Adamu  3   4 , Najibah A Galadanci  5   6 , Bashir Zubayr  7 , Chisom N Odoh  8 , Muktar H Aliyu  9   10
Affiliations
Meta-Analysis

Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis

Baba Maiyaki Musa et al. PLoS One. .

Abstract

Background: Multidrug resistant tuberculosis (MDR-TB), is an emerging public health problem in sub-Saharan Africa (SSA). This study aims to determine the trends in prevalence of MDR-TB among new TB cases in sub-Saharan Africa over two decades.

Methods: We searched electronic data bases and accessed all prevalence studies of MDR-TB within SSA between 2007 and 2017. We determined pooled prevalence estimates using random effects models and determined trends using meta-regression.

Results: Results: We identified 915 studies satisfying inclusion criteria. Cumulatively, studies reported on MDR-TB culture of 34,652 persons. The pooled prevalence of MDR-TB in new cases was 2.1% (95% CI; 1.7-2.5%). There was a non-significant decline in prevalence by 0.12% per year.

Conclusion: We found a low prevalence estimate of MDR-TB, and a slight temporal decline over the study period. There is a need for continuous MDR-TB surveillance among patients with TB.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA flow diagram showing study screening and selection procedure.
Fig 2
Fig 2. Forest plot showing pooled and individual weighted prevalence of included studies.
ES: effect size, CI: confidence interval.
Fig 3
Fig 3. Forest plot showing pooled MDR TB prevalence in new TB cases stratified by study design of included studies.
ES: effect size, CI: confidence interval.
Fig 4
Fig 4. Meta-regression plot showing sub-Saharan African (S SA) trend in MDR-TB prevalence in new cases over two decades.
P: MDR TB prevalence in new cases, circle size proportionate to size of studied population in each year.
Fig 5
Fig 5. Trim and filled funnel plot depicted study derived and data augmented prevalence of MDR-TB in new cases for SSA.
Theta: the effect (prevalence) estimate, SE: standard error; diamond shapes represent study derived prevalence; diamond within square represent data augmented prevalence.
See this image and copyright information in PMC

References

    1. WHO | Global tuberculosis report 2016. In: WHO. http://www.who.int/tb/publications/global_report/en/. Accessed 13 May 2017
    1. WHO | Tuberculosis. In: WHO. http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 1 Apr 2017
    1. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. (2012) Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 90:111–119D doi: 10.2471/BLT.11.092585 - DOI - PMC - PubMed
    1. Coker RJ (2004) Review: multidrug-resistant tuberculosis: public health challenges. Trop Med Int Health 9:25–40 - PubMed
    1. WHO | WHO End TB Strategy. In: WHO. http://www.who.int/tb/post2015_strategy/en/. Accessed 13 May 2017

MeSH terms